ERBB2 and breast cancer: CBX2 mRNA high expression was correlated to shorter RFS in BC patients with HER-2 negative tumors (HR=2.19, p=4.3e-07) (Figure 4E), but not in HER-2 positive tumors (HR=1.22, p=0.47) (Figure 4D).